ENSCHealthcare · BiotechnologyENSC Stock Forecast: Ensysce Biosciences, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 1 Aug 2026 — in the lower half.
ENSC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Ensysce Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Quality (15): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Ensysce Biosciences, Inc. — and when they’d sell — is the membership.
ENSC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ENSC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2023 | HC Wainwright & Co. | Maintains | Buy | $9.00 → $7.00 |
| 3 July 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 17 Nov 2022 | Lake Street | Maintains | Buy | $80 → $8.00 |
| 30 Nov 2021 | Lake Street | Initiates | Buy | $4.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ENSC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Ensysce Biosciences, Inc. (ENSC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- 0.9×
- Price / book
- −2.8×
- EV / EBITDA
- −0.3×
Cheaper than 73% of US stocks
Cheaper than 72% of US stocks
Cheaper than 95% of US stocks
Cheaper than 63% of US stocks
- Revenue growth (YoY)
- −27.2%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −370.7%
- Net margin
- −250.4%
Higher than 9% of US stocks
Higher than 9% of US stocks
Higher than 2% of US stocks
- Return on equity
- −1149.1%
- Return on assets
- −218.2%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ENSC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENSC appears on the weeks it earns a place.
Frequently asked questions about ENSC stock
How does Ticker Nerd's model rank ENSC?
As at 1 Aug 2026, Ensysce Biosciences, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
What is the ENSC stock forecast for 2030?
No analyst covering Ensysce Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $16 over the next 12 months.
How has ENSC stock performed over the past year?
Ensysce Biosciences, Inc. returned -86.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Ensysce Biosciences, Inc. do?
Ensysce Biosciences Inc. is a clinical-stage pharmaceutical company developing prescription therapeutics for severe pain and central nervous system conditions, including ADHD and opioid use disorder.
About Ensysce Biosciences, Inc.
Ensysce Biosciences Inc. is a clinical-stage pharmaceutical company developing prescription therapeutics for severe pain and central nervous system conditions, including ADHD and opioid use disorder. It leverages two proprietary prodrug platforms: TAAP™ (Trypsin-Activated Abuse Protection), which modifies active ingredients like oxycodone or amphetamine to remain inactive until exposed to trypsin in the small intestine, deterring tampering, injection, snorting, or chewing; and MPAR® (Multi-Pill Abuse Resistance), which incorporates a controlled-release trypsin inhibitor to limit active drug release in overdose scenarios, providing built-in protection. Lead programs include PF614, a TAAP™ extended-release oxycodone analogue in Phase 3 trials for post-surgical pain; PF614-MPAR, combining both platforms with FDA Breakthrough Therapy designation; PF8026 and PF8001 for ADHD; and PF9001 for opioid use disorder. These innovations aim to deliver effective analgesia and therapies while minimizing abuse, dependence, and overdose risks. Headquartered in La Jolla, California, Ensysce Biosciences Inc. operates in the pharmaceutical preparation manufacturing sector, focusing on tamper-resistant oral medications.
CEO Dr. D. Lynn Kirkpatrick Ph.D. · 8 employees · United States · https://www.ensysce.com